Catheter Precision (NYSEAMERICAN:VTAK) Releases Earnings Results, Beats Estimates By $18.02 EPS

Posted by Latisha Jones on Mar 31st, 2026

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($2.88) EPS for the quarter, topping the consensus estimate of ($20.90) by $18.02, FiscalAI reports. Catheter Precision had a negative return on equity of 208.54% and a negative net margin of 2,333.29%.

Catheter Precision Price Performance

VTAK traded down $0.04 during trading on Tuesday, hitting $1.01. The stock had a trading volume of 112,379 shares, compared to its average volume of 3,183,459. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.46 and a current ratio of 0.46. The company’s 50-day moving average price is $1.60 and its 200 day moving average price is $2.04. Catheter Precision has a twelve month low of $1.01 and a twelve month high of $15.68.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision as of its most recent SEC filing. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

(Get Free Report)

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.